Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB-1317 in Advanced/Metastatic Solid Tumors
NCT07141706Phase 1Recruiting
- Sponsor
- Duality Biotherapeutics
- Start
- Sep 2025
- Primary completion
- Jun 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of DB-1317 in solid tumor, gastric cancer (GC), colorectal cancer (CRC) and 1 more (9 arms), sponsored by Duality Biotherapeutics. Primary endpoints: Dose-Limiting Toxicities at 21 days, Treatment Emergent Adverse Events at 1 year and 7 more. Started Sep 2025; status: recruiting.
02
Drugs
DB-1317
03
Conditions
solid tumorgastric cancer (GC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07141706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07141706.